ACIP Recommends Recombinant Zoster Vaccine for Immunocompromised Adults Aged 19+

The Advisory Committee on Immunization Practices (ACIP) has published a recommendation report for the use of the Recombinant Zoster Vaccine (RZV) in immunocompromised adults aged 19 years and older in the United States. The recommendation is for a two-dose series to prevent herpes zoster and its related complications. This guidance is based on a review of existing evidence and expert consensus, not a new primary study.

No new efficacy, safety, or tolerability data from a specific study are reported in this recommendation. The report does not provide sample size, follow-up duration, comparator groups, or specific outcome measures. Details on adverse events, serious adverse events, and discontinuation rates are not reported.

Key limitations include the lack of new clinical trial data within this report; it is a synthesis of prior evidence into a formal public health recommendation. The practice relevance is that this constitutes an official ACIP guideline for vaccinating a broad population of immunocompromised adults. Clinicians should refer to the full ACIP statement and vaccine prescribing information for detailed guidance on administration, contraindications, and the evidence base supporting this recommendation.